How We Positioned a UK Life Sciences Company as a U.S. Authority in Pharmaceutical and Biotech Search

Getting noticed in U.S. search results as a foreign company is tougher than it seems. Local relevance, Google’s E-E-A-T standards, and strong U.S. pharmaceutical and biotech competitors make it a real challenge. When a UK life sciences firm asked us to help them reach U.S. pharmaceutical and biotech decision-makers, we realized that just targeting keywords wouldn’t be enough. We needed to build real search authority from the ground up using entity-based and semantic SEO. Here’s what we did.

What Made This Client’s Situation Unique

The company provided specialized contract research and scientific advisory services, with a solid reputation in Europe. However, U.S. search engines had little information about them. Google’s Knowledge Graph didn’t show any real links between the company and the main topics American buyers searched for, like clinical trial design, IND submissions, FDA regulatory strategy, CRO partnerships, and pharmaceutical outsourcing.

Their website had content, but it was clearly aimed at a European audience. It didn’t mention U.S. regulatory bodies like the FDA, or use American terminology and address local buyer concerns. From an entity SEO perspective, the site was missing the signals that show how key topics and organizations are connected—signals that U.S. competitors had built up over years. Before creating new content, we needed to understand exactly what was missing.

“When a company enters a new market, its biggest SEO obstacle is not keywords. It is an entity authority. Search engines need to understand who you are, what you do, and which established concepts you belong to. Building those connections through content is the real work.” — Emulent Marketing Strategy Team.

Step 1: Building the Entity Inventory and Identifying Association Gaps

We began with a full content audit focused on entity associations instead of just keyword rankings. Using Google’s Natural Language API and manual analysis of search results, we listed every entity the site currently mentioned. Then we compared this to what Google expects, based on the top-ranking U.S. competitors in pharmaceutical CRO and life sciences advisory content.

The gaps fell into three clear categories:

The three types of entity gaps we found:

• Critical Gaps: Core American regulatory entities—such as the FDA (Food and Drug Administration), IND (Investigational New Drug application), NDA (New Drug Application), and 505(b)(2) (a specific new drug approval route)—were completely absent from the site. These appear in more than 80% of top-ranking U.S. competitor pages in their category.
• Depth Gaps: Some entities, like “clinical trial phases,” were mentioned but never developed. They existed as isolated terms with no supporting context, comparisons, or associated concepts.
• Context Gaps: Entities such as “bioanalytical services” were mentioned in passing but were never properly linked to the company’s primary service entities. Google had no signal that these belonged together.

Step 2: Mapping Semantic Co-occurrence Patterns From U.S. Competitors

After finishing the gap analysis, we studied the five top-ranking U.S. life sciences service providers to see which entity pairs appeared together most often, how often they showed up in the same paragraph, and which combinations competitors hadn’t fully covered. These uncovered new opportunities for our client.

This analysis gave us a co-occurrence matrix to use in our content briefs. For instance, top-ranking pages often placed “FDA regulatory strategy” close to “Phase I clinical trials” and “IND submission”—but our client’s content didn’t, even though they offered all three services.

“Competitor co-occurrence analysis is one of the most underused tools in content strategy. You are not copying competitors. You are learning what Google already considers normal for a topic, so you can meet that baseline and then go further.” — Emulent Marketing Strategy Team.

What we learned from cross-competitor analysis:

• Consensus Gaps: Entity pairs used by four or more competitors that the client was missing entirely. These became mandatory inclusions in every relevant page.
• Leader Patterns: Specific entity combinations used by the top two ranking competitors. These received special attention in pillar content and service pages.
• White Space: Relevant entity pairings that no competitor covered well, particularly around EU-to-U.S. regulatory translation and cross-border development timelines. These became the foundation for content that genuinely differentiated the client.

Step 3: Creating Entity-Focused Content Briefs With Proximity and Frequency Guidelines: Drawing on these findings, we moved to transform our insights into actionable guidance for writers.

Once we finished the entity map, we created detailed content briefs for each planned page. These weren’t typical SEO briefs with just a keyword list and word count. Instead, each brief listed which entities should appear together, how often each should show up per 1,000 words, and where specific entity pairings needed to be placed in the content.

For example, in the main content about “pharmaceutical CRO services,” we made sure that “FDA regulatory strategy” appeared at least three times in the same paragraph as “IND submission.” The introduction needed to mention both the main entity and supporting regulatory bodies within the first 150 words. Each H2 section also had to mention the main service entity at least once.

How we structured each content brief:

• Tier 1 Entities (Required): Primary service terms and regulatory entities with minimum and maximum mention counts and required first-appearance placement.
• Tier 2 Entities (Recommended): Supporting concepts that add scientific credibility, with guidance on which sections to introduce them in.
• Tier 3 Entities (Value-Add): Differentiating terms that competitors did not fully cover, particularly around EU-U.S. cross-border drug development processes.
• Proximity Rules: Clear instructions for which entities must appear in the same paragraph, the same section, or within a set number of sentences of each other.

This level of detail helped our writers create content that felt natural to readers and built the exact entity relationships Google looks for.

“The brief is everything. When writers understand not just what to say but also where specific concepts need to appear relative to one another, the output is both search-smart and genuinely readable. Those two goals are not in conflict.” — Emulent Marketing Strategy Team.

Step 4: Content Production Targeting American Pharmaceutical and Biotech Decision-Makers

We had to change the writing style, terminology, and perspective. European regulatory language was replaced with FDA-focused language. When content mentioned EMA processes, we explained how those mapped to American equivalents, turning this into a real selling point instead of a drawback.

We built three types of content: service pages with detailed entity descriptions, educational articles that answered decision-maker questions, and authority content for U.S. readers who didn’t know the brand.

Content categories produced and their primary entity function:

• Service Pages: Built to satisfy Tier 1 entity requirements with precise proximity and frequency targets. These pages addressed specific CRO service offerings, with FDA and clinical-trial-entity co-occurrence baked in.
• Educational Articles: Targeted mid-funnel decision-maker questions using supporting entity clusters. These created the topical authority that service pages alone could not build.
• Cross-Border Regulatory Guides: White space content that no competitor had developed. These pages covered EU-to-U.S. drug development translation in practical terms, establishing the client as the only resource covering this specific angle.
• Author Profiles: Named scientific contributors with verifiable credentials. This directly supported Google’s E-E-A-T evaluation of the site and linked human experts to the company’s primary entities.

We also made sure all content met Google’s E-E-A-T standards (Experience, Expertise, Authoritativeness, and Trustworthiness), which are especially important for pharmaceutical topics. Using named authors with real credentials, mentioning specific regulatory processes like FDA approval, and using clear scientific terms all helped build stronger authority.

The Results: From Unknown to Recognized in U.S. Search

Within six months of launching the content program, the company went from page four or lower to consistently appearing on the first page for several important terms in pharmaceutical CRO and regulatory advisory searches. The unique content about EU-to-U.S. regulatory translation started ranking within 90 days, since there was little U.S. competition for those topics.

The biggest win wasn’t just better rankings. It was how Google started to see the company. By building the right entity relationships with well-structured content, the site changed from being an unknown foreign company to one that Google saw as truly relevant for American pharmaceutical and biotech searches.

“Rankings are an output. Entity authority is the input. When you build real topical relationships through content that covers subjects the way experts actually cover them, rankings follow. This case showed us that geography is not the obstacle people think it is when the entity strategy is right.” — Emulent Marketing Strategy Team.

What This Means for Life Sciences Companies Entering the U.S. Market

If you’re a pharmaceutical, biotech, or life sciences company looking for better U.S. search visibility, keyword lists and standard content briefs won’t get you far. The U.S. search market is competitive, and Google expects a lot from credible pharmaceutical or CRO websites. To meet those expectations, you need to know which entities to include, how they relate, and where your competitors have left gaps you can fill.

This process works for any organization entering a new market or trying to build authority in a field where they aren’t yet known. It takes patience and attention to detail, but the results build over time in ways that paid search can’t match.

If you’re facing similar challenges, our guide to modern entity-based SEO is a great starting point. You can also check out our broader life sciences marketing services and our specialized entity SEO and semantic optimization services to see how we help companies across the industry.

Ready to Build Real Search Authority for Your Life Sciences Brand?

Building U.S. search authority as a foreign life sciences company is a unique challenge that needs a tailored approach. We’ve done this before and know the common pitfalls. If your pharmaceutical or life sciences marketing isn’t giving you the visibility you want in the U.S., reach out to the Emulent team. We’ll review your current entity coverage and show you exactly what steps to take next.